These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30049503)

  • 1. Relative Oral Bioavailability of an Abuse-deterrent, Extended-release Formulation of Morphine Versus Extended-release Morphine: A 2-period, Single-dose, Randomized Crossover Study in Healthy Subjects.
    Kinzler ER; Pantaleon C; Aigner S
    Clin Ther; 2018 Aug; 40(8):1357-1365. PubMed ID: 30049503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.
    Webster LR; Pantaleon C; Iverson M; Smith MD; Kinzler ER; Aigner S
    Pain Res Manag; 2018; 2018():7276021. PubMed ID: 29849845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
    Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
    Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphine-Morphine ARER.
    Webster LR; Pantaleon C; Shah MS; DiFalco R; Iverson M; Smith MD; Kinzler ER; Aigner S
    Pain Med; 2017 Jul; 18(7):1303-1313. PubMed ID: 27651506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.
    Webster LR; Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Jul; 36(7):1730-1740. PubMed ID: 31065992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a New Amphetamine Extended-release Oral Liquid Suspension Under Fasted and Fed Conditions in Healthy Adults: A Randomized, Open-label, Single-dose, 3-treatment Study.
    Sikes C; Stark JG; McMahen R; Engelking D
    Clin Ther; 2017 Dec; 39(12):2389-2398. PubMed ID: 29174216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
    Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
    Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of the pharmacokinetic characteristics of an abuse-deterrent, extended-release, injection-molded morphine tablet.
    Dayno JM; Niebler G; Lawler J; Elhauge T; Lindhardt K
    J Opioid Manag; 2017; 13(2):111-124. PubMed ID: 28829526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers.
    Heinrich-Nols J; Schug BS; Evers G; Larsimont V; Elze M; Blume HH; Lee LS; Crawford F
    Int J Clin Pharmacol Ther; 1999 Mar; 37(3):153-8. PubMed ID: 10190764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release.
    Benedek IH; Jobes J; Xiang Q; Fiske WD
    Drug Des Devel Ther; 2011; 5():455-63. PubMed ID: 22162639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Food on the Pharmacokinetics of Single- and Multiple-Dose Hydrocodone Extended Release in Healthy Subjects.
    Bond M; Rabinovich-Guilatt L; Selim S; Darwish M; Tracewell W; Robertson P; Yang R; Malamut R; Colucci P; Ducharme MP; Spiegelstein O
    Clin Drug Investig; 2017 Dec; 37(12):1153-1163. PubMed ID: 28948482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
    Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
    Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
    Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
    BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.